Although the doses of Tregs infused were lower than what has been administered in type 1 diabetes,7 our highest dose was in the range of the number of Tregs contained within the cell product infused in the liver transplant trial from Japan (31‐466 × 106 CD4+ Foxp3+ T cells).11 The lack of signs of over‐immunosuppression is very reassuring, considering that the Tregs had been expanded under polyclonal conditions and were therefore potentially capable of exerting nonspecific suppressive effects. The gene discussed is FOXP3; the disease is type 1 diabetes mellitus.